FDA and USP Develop New Approaches for Glycosylation Analysis
This article was originally published in The Gold Sheet
Executive Summary
The growing number of biological products on the market is necessitating new approaches in the analysis and control of therapeutic glycoproteins. USP readies new chapters on glycosylation analysis and FDA describes high bar for approving manufacturing changes for protein therapeutic drugs.